Anagliptin, a Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients.
CONCLUSION: The present study suggests that anagliptin may exert a beneficial effect on arterial stiffness in patients with T2DM, which is independent of its blood glucose-lowering property. Anagliptin may ameliorate arterial stiffness partly via reduction of RLP cholesterol and improvement of liver function.
PMID: 27357182 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tahara N, Yamagishi SI, Bekki M, Kodama N, Nakamura T, Sugiyama Y, Oshige T, Kumashiro Y, Honda A, Tahara A, Igata S, Fukumoto Y Tags: Curr Vasc Pharmacol Source Type: research
More News: Cardiology | Cardiovascular | Chemistry | Cholesterol | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Glimepiride | Heart | Liver | Study | Urology & Nephrology